Vor Biopharma Inc.
VOR
$16.10
$1.177.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.57M | 16.77M | 14.42M | 2.40M | 6.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.16M | 35.96M | 29.14M | 243.55M | 33.29M |
| Operating Income | -35.16M | -35.96M | -29.14M | -243.55M | -33.29M |
| Income Before Tax | -219.59M | 1.72B | -812.68M | -1.57B | -32.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -219.59M | 1.72B | -812.68M | -1.57B | -32.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -219.59M | 1.72B | -812.68M | -1.57B | -32.49M |
| EBIT | -35.16M | -35.96M | -29.14M | -243.55M | -33.29M |
| EBITDA | -35.13M | -35.94M | -29.13M | -241.51M | -32.47M |
| EPS Basic | -5.11 | 84.89 | -121.63 | -251.24 | -5.21 |
| Normalized Basic EPS | -3.19 | 52.93 | -76.11 | -153.96 | -3.25 |
| EPS Diluted | -5.11 | 84.89 | -121.63 | -251.24 | -5.21 |
| Normalized Diluted EPS | -3.19 | 52.93 | -76.11 | -153.96 | -3.25 |
| Average Basic Shares Outstanding | 43.01M | 20.30M | 6.68M | 6.26M | 6.24M |
| Average Diluted Shares Outstanding | 43.01M | 20.30M | 6.68M | 6.26M | 6.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |